Navigation Links
BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
Date:6/4/2008

MOUNTAIN VIEW, California, June 4 /PRNewswire-FirstCall/ -- BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

A Phase I/II safety and tolerability study in 18 male patients with non-metastatic as well as hormone-insensitive prostate cancer has begun enrolment in the US. Secondary objectives of the trial include examining the ability of the vaccine to induce prostate antigen-specific immune responses, as well as clinical anti-tumor activity. Preliminary data is expected during second half year 2009.

The therapeutic vaccine, based on the company's MVA-BN(R) technology, is designed to generate cellular and humoral immune responses to PSA and PAP (prostate specific antigen and prostatic acid phosphatase), which are both well-known prostate cancer tumor targets.

Prostate cancer is, along with breast cancer, in the top three cancer market, each with more than 500,000 new diagnosed incidents globally per year and only limited treatment options.

Reiner Laus, MD, President & CEO of BN ImmunoTherapeutics said: "The initiation of clinical studies with our therapeutic prostate cancer vaccine advances our cancer portfolio and with both breast and prostate cancer vaccines in clinical development, we have now strengthened the cancer business area, which is an essential part of our group strategy going forward."

Located in Mountain View, California, BN ImmunoTherapeutics is a subsidiary of Bavarian Nordic, headquartered in Denmark.

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology, MVA-BN(R), has been demonstrated in clinical trials to be one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbol BAVA.

For more information, please visit: http://www.bavarian-nordic.com

"Safe Harbour" Statement under the Private Securities Litigation Reform Act of 1995:

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. No "forward-looking statement" can be guaranteed, and actual results may differ materially from those projected. Bavarian Nordic undertakes no obligation to publicly update any "forward-looking statement", whether as a result of new information, future events, or otherwise. Additional information regarding risks and uncertainties is set forth in the current Annual Report and in Bavarian Nordic's periodic reports, if any, which we incorporate by reference.


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
2. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
6. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
7. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
8. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
9. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
10. Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms
11. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , January 24, 2017 For today, ... GENE ), Alder Biopharmaceuticals Inc. (NASDAQ: ... ), and Egalet Corp. (NASDAQ: EGLT ). These ... lower on Monday, January 23 rd , 2017, with the ... health care companies in the S&P 500 also were down ...
(Date:1/24/2017)... 23, 2017 Optoelectronic components have the ... The interaction of these components with light makes ... range of applications. These components are primarily used ... and healthcare among others. Growing application ... low power consumption, reliability, scalability, and performance is ...
(Date:1/24/2017)... 2017 Laboratory Markets Limited has completed a ... spectrometry in both clinical and research laboratory settings. This ... size of $6.8 billion and growing to $9.2 billion ... the use of mass spectrometry across more than 5,200 ... investigated growth in the use of mass spectrometry in ...
Breaking Medicine Technology:
(Date:1/24/2017)... , ... January 24, 2017 , ... ... (AMIA) commended the Patient-Centered Outcomes Research Institute (PCORI) for developing a data access ... PCORI consider requiring a preliminary data sharing plan as part of award applications, ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... offering, Processing Assurance Control Equipment (PACE), at the International Production and Processing Expo ... booth will highlight the new technology that is used in poultry processing facilities ...
(Date:1/24/2017)... ... 2017 , ... Learn to use popular brainwave and heart rhythm equipment to ... offered by Dr. Carol Francis at PVNET on Sundays in February and March and ... experiences. , Dr. Carol Francis shows business owners, parents, athletes, students and ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... that it has officially formed a distribution partnership with Byers Scientific & ... odor management industry. , Through the agreement, OMI Industries formulated a special version ...
(Date:1/24/2017)... ... January 24, 2017 , ... This Saturday, January 28, the ... a very special performance by Alabama Symphony Orchestra musicians Yifan Zhou, Mara McClain & ... as dim sum, and exhibitors offer a look at Chinese games, crafts & more. ...
Breaking Medicine News(10 mins):